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Abstract
Background: Sulphadoxine-pyrimethamine, in combination with artesunate or amodiaquine, is recommended for
the treatment of uncomplicated malaria and is being evaluated for intermittent preventive treatment. Yet, limited
data is available on pharmacokinetic interactions between these drugs.
Methods: In a randomized controlled trial, children aged 6-59 months with uncomplicated falciparum malaria,
received either one dose of sulphadoxine-pyrimethamine alone (SP), one dose of SP plus three daily doses of
amodiaquine (SP+AQ) or one dose of SP plus 3 daily doses of artesunate (SP+AS). Exactly 100 μl of capillary blood
was collected onto filter paper before drug administration at day 0 and at days 1, 3, 7, 14, 21 and 28 after drug
administration for analysis of sulphadoxine and pyrimethamine pharmacokinetic parameters.
Results: Fourty, 38 and 31 patients in the SP, SP+AQ and SP+AS arms, respectively were included in this study.
The concentrations on day 7 (that are associated with therapeutic efficacy) were similar between the SP, SP+AQ
and SP+AS treatment arms for sulphadoxine (median [IQR] 35.25 [27.38-41.70], 34.95 [28.60-40.85] and 33.40 [24.63-
44.05] μg/mL) and for pyrimethamine (56.75 [46.40-92.95], 58.75 [43.60-98.60] and 59.60 [42.45-86.63] ng/mL). There
were statistically significant differences between the pyrimethamine volumes of distribution (4.65 [3.93-6.40], 4.00
[3.03-5.43] and 5.60 [4.40-7.20] L/kg; p = 0.001) and thus elimination half-life (3.26 [2.74 -3.82], 2.78 [2.24-3.65] and
4.02 [3.05-4.85] days; p < 0.001). This study confirmed the lower SP concentrations previously reported for young
children when compared with adult malaria patients.
Conclusion: Despite slight differences in pyrimethamine volumes of distribution and elimination half-life, these
data show similar exposure to SP over the critical initial seven days of treatment and support the current use of SP
in combination with either AQ or AS for uncomplicated falciparum malaria treatment in young Malian children.
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Malaria remains a major public health problem, particu-
larly in sub-Saharan Africa, where it claims nearly
750,000 lives of children under the age of five years [1].
To improve cure rates and delay the development and
spread of artemisinin resistance, the World Health
Organization (WHO) recommends artemisinin-based
combination therapy (ACT) [2]. Nearly all malaria ende-
mic countries and territories worldwide have adopted
ACT as first-line treatment for Plasmodium falciparum
malaria [1]. However, many studies show fewer treat-
ment failures by day 28 when sulphadoxine-pyrimetha-
mine (SP) is combined with amodiaquine (AQ) rather
than artesunate (AS) [3-5]. SP monotherapy is the only
drug recommended for intermittent preventive treat-
ment during pregnancy (IPTp) and SP+AQ is a strong
candidate for IPT in infants (IPTi) and in children
(IPTc) [4-11].
Resistance to SP is wide spread in Africa, with high
level of resistance in east Africa compared to west
Africa. That is confirmed by the level of dhfr and dhps
mutation levels, particularly dhps540 which best predicts
the in vivo SP resistance [12].
Despite some level of resistance to SP and AQ, the
combination of the two drugs is effective on falciparum
malaria in much of West Africa.
And, despite these widespread use of SP, the pharma-
cokinetic parameters of SP when used in combination
with AS or AQ is poorly documented, particularly in
young children. Altered pharmacokinetic parameters
contribute to the increased risk of young children failing
SP treatment. After adjusting for dosage, median sulpha-
doxine and pyrimethamine areas under the concentra-
tion time curves in children aged 2-5 years old are
approximately half those in adults [13]. This study
investigated the effect of combination with either AQ or
AS on SP pharmacokinetic parameters in children
under-five years of age enrolled in a randomized con-
trolled trial on the treatment of uncomplicated falci-
parum malaria.
Methods
Study design
This was an open label clinical trial using the WHO
2003 protocol [14] conducted in Bancoumana, Mali,
during the malaria transmission seasons of 2004 (August
2004-January 2005) and 2005 (July 2005-January 2006).
Bancoumana is a rural village of around 12,000 people
located 60 kilometers south-west of Bamako. Plasmo-
dium falciparum malaria is both endemic and seasonal
with parasitaemia prevalence rates ranging from 40-50%
in the dry season (October-May) and 70-85% in the
rainy season (June-September)[15,16]. Inclusion criteria
for this study included 1) parental consent; 2) age
between 6 and 59 months; 3) an axillary temperature
between 35.5°C and 39.5°C; and 4) P. falciparum mono-
specific parasitaemia between 2,000 and 200,000 para-
sites/ul (parasite density was measured by microscopy
after staining thick smear with Giemsa). Exclusion cri-
teria included 1) features of severe malaria (haemoglobin
< 5 g/dL; respiratory distress, renal failure; hypoglycae-
mia, shock; bleeding), 2) danger signs such as prostra-
tion, 3) a history of allergy or other severe adverse
reaction to the study drugs and 4) more than two epi-
sodes of vomiting per day. Children with any of the
above exclusion characteristics or who were considered
too ill for inclusion in the study, or who declined to par-
ticipate in the study, received standard and appropriate
treatment with chloroquine as then recommended by
the National Malaria Control Programme.
Enrolled children were randomized into three treat-
ment arms (SP, SP+AQ or SP+AS) by computer-gener-
ated randomization. Directly observed treatment was
administered based on weight to the nearest half tablet
that would provide the following minimum dose(s): 25
mg/kg of sulphadoxine and 1.25 mg/kg of pyrimetha-
mine as a single dose on day 0; with or without AQ 10
mg/kg/day over three days or artesunate 4 mg/kg/day
over three days. All subjects were observed for 60 min-
utes to monitor for adverse reactions and to make sure
that the medicine was not vomited. If vomiting occurred
within 30 minutes, the full dose was re-administered. If
vomiting occurred between 30 and 60 minutes a half-
dose was re-administered. All acute concomitant ill-
nesses were treated for free by the study team, with con-
comitant medication which had no known SP drug
interactions. Parental written informed consent was
obtained before any protocol specific procedure was
performed. The study was conducted in accordance
with the Helsinki Declaration of 1975 (as revised in
1983). The protocol was approved by the ethical com-
mittee of the Faculty of Medicine, Pharmacy and
Odonto-Stomatology, Bamako, Mali.
Study drugs quality
Study drugs (Flavoquine
® tablet for AQ, Fansidar
®
tablet for SP and Artesunate tablet for AS)were bought
at a private pharmacy in Bamako, Mali. The quality of
these drugs were authenticated according to the United
States Pharmacopoeia and National Formula (USP-NF)
2004 methods using dissolution testing apparatus in
combination with High Performance Liquid Chromato-
graphy (17). More than 75% of the amount of the three
drugs (sulphadoxine, pyrimethamine and amodiaquine)
of the study were dissolved in the time indicated for
each drug.
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Capillary blood samples were collected by fingerprick at
day 0 prior to treatment and on days 1, 3, 7, 14, 21 and
28, after SP administration into 1.5 ml Eppendorf tubes
without anticoagulant. Exactly 100 μl of that blood sam-
ple was spotted onto filter paper (Whatman 3 M), air
d r i e da tr o o mt e m p e r a t u r ea n ds t o r e di np l a s t i cf o l d e r s
with solid desiccant until assayed in March 2008. Con-
centrations of sulphadoxine and pyrimethamine were
determined by a validated method using liquid chroma-
tography-mass spectrometry/mass spectrometry, with
the lower limits of quantification set at 10 μg/mL for
sulphadoxine and 10 ng/mL for pyrimethamine. The
upper limits of quantification were set at 200 μg/mL for
sulphadoxine and 1 μg/mL for pyrimethamine. The
coefficient of variation for sulphadoxine was 10.3% at 65
μg/mL, and pyrimethamine had a coefficient of variation
of 13.8% at165 ng/mL as previously described [13].
Pharmacokinetic analysis
The area under the capillary blood concentration-time
curve to infinity (AUC), terminal elimination half-life
(t1/2), apparent volume of distribution (VD) and appar-
ent clearance (Cl) of pyrimethamine and sulphadoxine
were determined using a non compartmental model in
WinNonLin Professional 3.3 (Pharsight). As there was
no intravenous comparator arm in this study, equivalent
bioavailability was assumed for comparisons of apparent
volumes of distribution and clearance, which were
expressed as Vd/f and Cl/f, where f is the fraction of
drug absorbed (unknown).
Statistical analysis
As most pharmacokinetic parameters were not normally
distributed, these were summarized using medians and
inter-quartile ranges and compared between the three
treatment arms using the Kruskal-Wallis equality-of-
populations rank test. Categorical data were compared
using the Chi-squared test.
Results
Study population characteristics
Between 2004 and 2006, we conducted a clinical trial
comparing the therapeutic efficacy of SP, SP+AQ and
SP+AS. A total of 455 children were included and 441
(97%) were successfully followed for 28 days. The base-
line characteristics in the three treatment arms were
comparable for mean age, mean weight and gender (P >
0.05). Without PCR correction the 28-day uncorrected
adequate clinical and parasitological response (ACPR)
rates were above 95% for each of the treatment arms.
Early treatment failure (ETF) was only found in the SP-
monotherapy arm in three patients (2%, n = 147). After
PCR correction by msp2, the ACPR rates were above
97% in all three groups.
Among the study population children with complete
pharmacokinetic samples from day 0 to day 28 were
included in this pharmacokinetic analysis i.e. 41 children
in SP arm, 40 in SP+AQ and 33 in SP+AS. The ages of
the children enrolled ranged between 10 and 60 months.
Treatment groups were well matched for the baseline
characteristics of age, gender, weight, SP mg/kg dosage,
temperature and hemoglobin (Table 1). Three patients
who vomited within 60 minutes (one in each treatment
arm), and one patient with quantifiable SP concentra-
tions pre-treatment (day 0) and one patient (SP+AQ
arm) in whom SP concentrations were below the limits
of quantification throughout the follow up period were
excluded from the analysis of pharmacokinetic para-
meters. This analysis was performed on a total of 40, 38
and 31 patients respectively in the SP, SP+AQ and SP
+AS arms (Figure 1).
Pharmacokinetic analysis
The three treatment arms had similar mean concentra-
tion time profiles of sulphadoxine (Figure 2) and pyri-
methamine (Figure 3) with almost all children reaching
the maximum concentration on Day 1 (103/109 (95%)
for sulphadoxine and 107/109 (99%) for pyrimethamine.
For sulphadoxine, the day 1, 3, and 7 concentrations as
well as the AUC, apparent volume of distribution,
apparent clearance and elimination half-life were similar
between the three treatments arms (P > 0.05) (Table 2).
For pyrimethamine, the day 1, 3, and 7 concentrations
as well as the AUC and apparent clearance were similar.
However, the apparent volume of distribution of pyri-
methamine was lower in the SP+AQ arm when com-
pared to SP monotherapy (p = 0.008) and SP+AS (p <
0.001) treatment arms. As a consequence the elimina-
tion half-life was lower in patients treated with SP+AQ
Table 1 Baseline characteristics [median (IQR)] by
treatment group
SP arm
(n = 41)
SP+AQ arm
(n = 40)
SP+AS arm
(n = 33)
P-value
Age (months) 48 48 48 0.66
(24-48) (24-48) (24-48)
Gender Male 21/41 23/40 19/33 0.81
n (%) (51%) (58%) (58%) (Chi-squared)
Weight (kg) 14 13.5 13 0.93
(11-16) (12-16) (11-15)
Temperature 38.5 38.7 38.2 0.50
(Celcius) (38.0-38.9) (38.1-39.1) (37.8-39.0)
Haemoglobin 10.7 10.3 10.9 0.95
(g/dL) (9.5-11.8) (9.4-12.20 (8.9-11.7)
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The apparent Volume of distribution for pyrimethamine
was also lower following SP monotherapy than SP+AS
(p = 0.030) (Table 3).
As previously reported this study showed relatively
wide inter-individual variation with Coefficients of varia-
tion of 29.8% and 48.7% for Day-7 concentrations of sul-
phadoxine and pyrimethamine, respectively.
The child who was retreated with a half-dose follow-
ing vomiting between 30 and 60 minutes had SP con-
centrations similar to the medians on day 1 (77.7 μg/ml
for sulphadoxine and 234 ng/ml for pyrimethamine).
The two children retreated with the full dose for vomit-
ing within 30 minutes had SP concentrations on day 1
that were almost double the median (133 and 137 μg/ml
for sulphadoxine and 513 and 661 ng/ml for pyrimetha-
mine). There were no serious adverse events during this
study.
Discussion
This study reports on SP pharmacokinetic parameters in
young African children with uncomplicated P. falci-
parum malaria in the context of combination therapies,
and confirmed the lower SP concentrations previously
reported for this age group when compared with adult
malaria patients [13]. There was no statistically signifi-
cant difference between sulphadoxine and pyrimetha-
mine concentrations (at day 1, day 3 and day 7), AUC
and elimination half-life between the SP monotherapy
and SP+AS arms. AS having no impact on these SP
441patientscompleted
28ͲdayfollowͲup
147patientsin
SParm
147patientsin
SP+AQarm
147patientsin
SP+ASarm
Samplesfrom41
patientswereassayed
byHPLC–M S / M S
Samplesfrom40
patientswereassayed
byHPLC–M S / M S
samplesfrom33
patientswereassayed
byHPLC–M S / M S
1caseofvomiting
within60minutesof
drugadministration
1caseofvomiting
within30minutes
ofadministration
1caseofvomiting
within30minutes
ofadministration
1caseofquantifiable
SPconcentrationin
pretreatmentblood
1patientwithSulfadoxine
concentrationbelowthe
limitofquantification
duringfollowupdays
40patients
analyzableinSP
arm
38patients
analyzableinSP+AQ
arm
31patients
analyzableinSP
+ASarm
Figure 1 Study profile.
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previously reported in healthy adults when AS was
administered concomitantly with SP [18] and is reassur-
ing, supporting the use of AS in combination with SP.
However, a higher volume of distribution of pyrimetha-
mine in the SP + AS arm when compared to SP mono-
therapy arm was observed in this study [median 5.60 vs.
4.65 L/kg; p = 0.030 (Table 3)].
Although adding amodiaquine to SP had no effect on
sulphadoxine pharmacokinetic parameters, a significant
decrease in the apparent volume of distribution and
elimination half-life of pyrimethamine in the SP+AQ
arm was observed. However, this did not result in a sig-
nificant change in pyrimethamine concentrations in the
blood in SP+AQ arm over the critical initial seven days
of treatment nor the AUC. The absence of a substantial
PK interaction in our study population supports the
effectiveness of SP+AQ in IPTc [7,10] and in uncompli-
cated falciparum malaria tre a t m e n ti nc h i l d r e nu n d e r
five [5]. The effect of the shorter pyrimethamine elimi-
nation half-life could possibly reduce the post-treatment
prophylactic effect of sulphadoxine-pyrimethamine plus
amodiaquine as resistance to these partner drugs
increases.
Day-7 concentrations of sulphadoxine and pyrimetha-
mine are a good surrogate measure of their respective
total whole blood AUCs [13] and Day 7 concentration is
a predictor of treatment outcome [19]. Day7 pyrimetha-
mine concentration observedi nt h i ss t u d yw a ss l i g h t l y
higher in SP+AQ arm, but this difference was not statis-
tically significant (Figure 3). When compared with SP
Day-7 capillary blood concentrations previously pub-
lished for children aged 2-5 years in southern Africa
[sulphadoxine median 31.3 (IQR 19.7-52.0); pyrimetha-
mine median 70.3 (IQR 39.0-101.9)],[13] day-7 concen-
trations in young Malian children were similar for
sulphadoxine, but appeared lower for pyrimethamine.
The vast majority of our patients achieved maximum
concentrations of both sulphadoxine and pyrimethamine
on day 1. However, the exact Cmax and Tmax could
not be determined precisely because of limited sampling
frequency. The concentration of artesunate could not be
quantified because of the sampling methodology used,
and the concentrations and pharmacokinetic parameters
of amodiaquine (when administered with SP) will be
reported separately.
The two children who were retreated with the full
dose after vomiting within 30 minutes of SP
Figure 2 Mean Sulphadoxine concentration profiles in young Malian children with uncomplicated falciparum malaria, by treatment
arm.
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SP concentrations on day 1, suggesting that further
data is needed to inform optimal dosing in patients
with early vomiting.
In this study conducted in Mali in 2004-2006, SP or
its combination with AS or AQ remained highly effec-
tive with more than a 95% adequate clinical and para-
sitological response rate. Although this level of efficacy
Figure 3 Mean Pyrimethamine concentration profiles in young Malian children with uncomplicated falciparum malaria, by treatment
arm.
Table 2 Sulphadoxine pharmacokinetic parameters (Median [IQR]) in Malian children under five with uncomplicated
falciparum malaria, by treatment group
PARAMETERS SP arm SP+AQ arm SP+AS arm P-value
[Kruskal-Wallis]
Sulphadoxine dose (mg/kg) 27.8
(25.0-27.8)
28.8
(25-31.3)
27.8
(25-28.8)
0.46
Median Concentration day 1
[IQR] (μg/mL)
73.20
[66.55-89.33]
80.95
[65.05-89.08]
76.80
[62.70-93.50]
0.86
Median Concentration day 3
[IQR] (μg/mL)
61.3
[47.8-73.0]
63.9
[49.6-72.7]
57.9
[47.4-69.8]
0.71
Median Concentration day 7
[IQR] (μg/mL)
35.25
[27.38- 41.70]
34.95
[28.60-40.85]
33.40
[24.63-44.05]
0.97
Median AUC [IQR]
(μg/mL.day)
660.08
[520.37-832.11]
682.67
[579.45-797.12]
672.04
[525.35-898.86]
0.88
Median VD [IQR]
(mL/kg)
349.35
[295.43-434.25]
345.60
[294.15-427.95]
357.80
[266.70-427.40]
0.97
Median T1/2 [IQR]
(days)
5.60 [4.62-6.78] 5.77 [5.11-6.45] 6.13 [4.90-7.26] 0.56
Median Clearance [IQR] (mL/kg/day) 41.85
[35.13-54.78]
41.65
[34.20-52.83]
41.00
[32.10-53.40]
0.80
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either AS or AQ is quite high in comparison with data
from Eastern or Southern Africa [20,21], these rates
are common in West Africa [22-24] and may reflect
the lower frequency of dihydrofolate reductase (dhfr)
and dihydropteroate synthetase (dhps) mutations asso-
ciated with SP resistance [25,26]. Probably because of
their strong synergy, the minimum effective concentra-
tions (MEC) of sulphadoxine and/or pyrimethamine
have not been clearly defined. In Gabon, where the
prevalence of DHFR triple mutation was ~70%, day 3
concentrations associated with treatment success were
100 μg/mL for sulphadoxine and 175 ng/mL pyri-
methamine [27]. Of the 109 children in this study,
only 4 (3.7%) and 40 (36.7%) achieved these ‘therapeu-
tic’ day-three concentrations of sulphadoxine and pyri-
methamine, respectively. This might suggest that as
dhfr/dhps mutations accumulate the SP concentrations
achieved may be insufficient to ensure an adequate
clinical and parasitological response rate as recently
described in Malawi [28].
Conclusion
This pharmacokinetic data supports the current use of
SP in combination with AS to treat young Malian chil-
dren with uncomplicated falciparum malaria, and the
use of SP + AQ for IPTc. Ongoing monitoring is essen-
tial, particularly given the lower pyrimethamine concen-
trations and the accumulation of dhfr and dhps
mutations that typically occurs in areas with large-scale
deployment of SP.
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